RA Capital Management L.P. lifted its stake in Vor Biopharma Inc. (NYSE:VOR - Free Report) by 74.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,646,039 shares of the company's stock after acquiring an additional 16,897,159 shares during the period. RA Capital Management L.P. owned approximately 57.73% of Vor Biopharma worth $44,007,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in Vor Biopharma in the 4th quarter valued at $33,000. Virtu Financial LLC purchased a new position in Vor Biopharma during the fourth quarter worth about $60,000. XTX Topco Ltd bought a new position in Vor Biopharma in the 4th quarter worth about $80,000. Northern Trust Corp raised its holdings in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Finally, Lynx1 Capital Management LP bought a new stake in shares of Vor Biopharma during the 4th quarter valued at about $707,000. Hedge funds and other institutional investors own 97.29% of the company's stock.
Wall Street Analyst Weigh In
VOR has been the topic of several research analyst reports. Stifel Nicolaus decreased their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. HC Wainwright dropped their price objective on shares of Vor Biopharma from $17.50 to $13.00 and set a "buy" rating for the company in a report on Friday, March 21st. Oppenheimer restated an "outperform" rating and set a $8.00 price target on shares of Vor Biopharma in a research report on Friday, March 21st. Finally, Wedbush reiterated an "outperform" rating and issued a $7.00 price objective on shares of Vor Biopharma in a report on Thursday, March 20th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.86.
Get Our Latest Report on VOR
Vor Biopharma Stock Down 4.7 %
Shares of Vor Biopharma stock traded down $0.03 on Tuesday, hitting $0.58. The stock had a trading volume of 179,380 shares, compared to its average volume of 586,738. The stock has a market cap of $71.91 million, a price-to-earnings ratio of -0.35 and a beta of -0.21. The stock's 50-day simple moving average is $0.76 and its two-hundred day simple moving average is $0.98. Vor Biopharma Inc. has a one year low of $0.49 and a one year high of $1.87.
About Vor Biopharma
(
Free Report)
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Featured Stories
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
